Europe
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.
QED Therapeutics, an affiliate of BridgeBio Pharma, announced today their global collaboration and licensing agreement with Helsinn Group.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
Citing Russia’s agricultural regulatory agency, Reuters reported the new vaccine called Carnivac-Cov will be used against the virus in dogs, cats, foxes and mink.
Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.
After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.
PRESS RELEASES